[Form 4] Structure Therapeutics Inc. Insider Trading Activity

Rhea-AI Filing Summary

Structure Therapeutics insider transaction: Reporting person Ashley Hall, identified as Chief Development Officer and a director, had 6,021 ordinary shares withheld to satisfy income tax obligations related to the vesting of restricted share units on 09/18/2025. The shares were recorded at a price of $7.7433 per share and reduced Hall's beneficial ownership to 112,317 ordinary shares. The filing notes that the issuer's ordinary shares may be represented by ADSs, with each ADS equal to three ordinary shares. This appears to be a routine tax-withholding disposition following equity vesting rather than an open-market sale.

Insights

Securities Analyst

TL;DR: Routine tax-withholding disposition after RSU vesting; limited immediate market impact.

The transaction is a standard corporate practice where the issuer withholds shares to cover income tax from equity compensation. The size—6,021 shares—reduces the insider's stake to 112,317 shares, which is modest relative to typical public-company float sizes and therefore unlikely to materially affect supply-demand dynamics for GPCR. The disclosed per-share price of $7.7433 is the withholding valuation and not an open-market sale price; investors should treat this as administrative rather than directional insider selling.

Corporate Governance Expert

TL;DR: Administrative withholding for tax obligations indicates compensation settlement, not opportunistic divestiture.

This Form 4 reports shares withheld to satisfy tax liabilities on vested restricted share units, a common practice aligned with standard compensation and governance policies. The reporting person is both an officer and director, and the filing confirms continued beneficial ownership after the withholding. There are no indications of extraordinary executive departures, related-party transactions, or change-in-control issues in this disclosure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hall Ashley

(Last) (First) (Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	09/18/2025		F		6,021(2)	D	$7.7433	112,317	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.

2. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award.

	/s/ Jun Yoon, Attorney-in-Fact	09/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Structure Therapeutics (GPCR) report?

The filing shows 6,021 ordinary shares were withheld to satisfy taxes on vested restricted share units; this is an administrative disposition, not an open-market sale.

Who is the reporting person on the GPCR Form 4?

The reporting person is Ashley Hall, identified as the company's Chief Development Officer and a director.

How many shares does Ashley Hall own after the transaction (GPCR)?

Following the withholding, Ashley Hall beneficially owns 112,317 ordinary shares.

What price was used for the withheld shares in the GPCR filing?

The shares withheld were reported at a per-share value of $7.7433.

Was this reported transaction an open-market sale for GPCR?

No; the filing states the shares were withheld by the issuer to satisfy income tax obligations related to RSU vesting, not sold on the open market.